(Codrituzumab)Biosimilar Reference Antibody-GS40142 新品

货号：GS40142

Codrituzumab (also known as GC33 or RG-7597) is an investigational humanized monoclonal antibody that was developed as a targeted therapy for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It was designed to bind specifically to an antigen that is highly expressed on the surface of HCC tumor cells but largely absent from healthy liver tissue. Despite a strong preclinical rationale, the drug’s clinical development in later-stage trials did not demonstrate a significant survival benefit over existing standard of care, and its development appears to have been discontinued.